Why Strategic Fit Has Become Healthcare M&A's Most Valuable Currency

Healthcare dealmakers have spoken. When asked what matters most when evaluating an acquisition target, 42% of respondents selected strategic fit, ahead of patient/customer base (35%) and financial performance (23%).

At first glance, the result may seem surprising. Healthcare has spent the last several years navigating margin pressure, reimbursement uncertainty, labor shortages, and rising capital costs. Conventional wisdom would suggest buyers are becoming more financially disciplined.

Instead, the survey suggests the opposite. Financial performance remains important, but it is no longer the primary lens through which many healthcare acquisitions are evaluated.

The reason is simple. Today's healthcare market rewards positioning more than optimization.

Across healthcare services, healthtech, provider groups, and life sciences, buyers are increasingly searching for assets that strengthen competitive advantages, expand capabilities, or provide access to attractive growth markets. A target's ability to accelerate a strategic roadmap may now carry more weight than its most recent earnings profile.

This trend is particularly visible in healthcare services. Revenue cycle management, physician services, specialty platforms, and technology-enabled outsourcing businesses continue to command premium valuations despite broader market volatility. Buyers are often underwriting future operational leverage, customer expansion opportunities, and platform consolidation potential rather than focusing exclusively on historical financial metrics.

The survey's second-ranked factor, patient and customer base at 35%, reinforces this shift.

Healthcare remains one of the most relationship-driven industries in the economy. Access to patients, providers, payers, employers, and health systems has become increasingly difficult and expensive to build organically. As a result, customer concentration is no longer viewed solely as a diligence risk. In many cases, it represents a strategic asset.

For healthcare technology companies, a deeply embedded customer base can create switching costs that are difficult for competitors to overcome. For provider organizations, patient access points increasingly determine long-term growth potential. For pharmaceutical and medical technology companies, commercial reach often matters as much as product innovation.

The finding that only 23% of respondents ranked financial performance as the most important factor should not be interpreted as a dismissal of profitability. Rather, it reflects a growing recognition that financial results are often backward-looking, while strategic fit determines future value creation.

Many of healthcare's most successful acquisitions generated returns not because the acquired company had superior financial performance at closing, but because the transaction unlocked synergies, expanded market access, strengthened data assets, or created new operating capabilities.

This is particularly relevant as artificial intelligence, automation, and value-based care continue to reshape the industry. Buyers increasingly need assets that can help them navigate structural change rather than simply add revenue.

The broader implication is that healthcare M&A is becoming more selective, not less disciplined. Buyers are willing to pay for assets that solve strategic problems, but they are becoming less willing to pay simply for growth or scale alone.

The winners in the next cycle are likely to be organizations that can clearly articulate how an acquisition strengthens their long-term position in the market.

The survey result offers a useful reminder. In healthcare M&A, balance sheets still matter. But strategy is increasingly what determines who wins.